Treatment of chronic hepatitis C: current and future
- PMID: 23463207
- DOI: 10.1007/978-3-642-27340-7_13
Treatment of chronic hepatitis C: current and future
Abstract
Resolution of the three-dimensional structures of several Hepatitis C virus (HCV) proteins, together with the development of replicative cell culture systems, has led to the identification of a number of potential targets for direct-acting antiviral agents (DAA). Numerous families of drugs that potently inhibit the HCV life cycle in vitro have been identified, and some of these molecules have reached early to late clinical development. Two NS3-4A protease inhibitors, telaprevir and boceprevir, were approved in Europe and the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1. A number of other DAAs are at the clinical developmental stage in combination with pegylated IFN-α and ribavirin or with other DAAs in IFN-free regimens, with or without ribavirin. They include second-wave, first-generation, and second-generation NS3-4A protease inhibitors, nucleoside/nucleotide analogue inhibitors, and non-nucleoside inhibitors of HCV RNA-dependent RNA polymerase, inhibitors of nonstructural protein 5A and host-targeted agents, such as cyclophilin A inhibitors and microRNA-122 antagonists. The proof of concept that IFN-free regimens can lead to HCV eradication has recently been brought. This chapter provides an overview of the current treatment of HCV infection and discusses the future of HCV therapy with new anti-HCV drugs.
Similar articles
-
Antiviral strategies in hepatitis C virus infection.J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. J Hepatol. 2012. PMID: 22300469 Review.
-
Hepatitis C virus: standard-of-care treatment.Adv Pharmacol. 2013;67:169-215. doi: 10.1016/B978-0-12-405880-4.00005-6. Adv Pharmacol. 2013. PMID: 23886001 Review.
-
New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.Semin Liver Dis. 2014 Feb;34(1):22-9. doi: 10.1055/s-0034-1371007. Epub 2014 Apr 29. Semin Liver Dis. 2014. PMID: 24782255 Review.
-
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4. J Infect. 2014. PMID: 24012819 Review.
-
[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].Harefuah. 2012 Dec;151(12):709-14, 719. Harefuah. 2012. PMID: 23330266 Hebrew.
Cited by
-
Management of hepatitis c genotype 4 in the liver transplant setting.Saudi J Gastroenterol. 2016 May-Jun;22(3):173-82. doi: 10.4103/1319-3767.182453. Saudi J Gastroenterol. 2016. PMID: 27184634 Free PMC article. Review.
-
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design.FEBS J. 2014 Sep;281(18):4085-96. doi: 10.1111/febs.12936. Epub 2014 Aug 11. FEBS J. 2014. PMID: 25039866 Free PMC article. Review.
-
Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study.Semin Liver Dis. 2014 Feb;34(1):98-107. doi: 10.1055/s-0034-1371083. Epub 2014 Apr 29. Semin Liver Dis. 2014. PMID: 24782263 Free PMC article.
-
The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection.Oncotarget. 2018 Jan 10;9(13):11291-11302. doi: 10.18632/oncotarget.24129. eCollection 2018 Feb 16. Oncotarget. 2018. PMID: 29541414 Free PMC article.
-
Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis.Infect Immun. 2014 Apr;82(4):1698-709. doi: 10.1128/IAI.01564-13. Epub 2014 Feb 3. Infect Immun. 2014. PMID: 24491580 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
